Just saw that Kyowa Kirin is taking back full control of rocatinlimab from Amgen after they ended their collaboration. Apparently Amgen did a portfolio review and decided to step back, but here's the interesting part - the Phase 3 trials actually looked solid. Both ROCKET-IGNITE and ROCKET-HORIZON hit their endpoints last November, and the data showed real skin clearance benefits for atopic dermatitis patients.

What caught my attention is the long-term extension study data showing the drug could work with extended dosing intervals. For a moderate-to-severe atopic dermatitis treatment, that's actually pretty meaningful - means fewer injections potentially. The mechanism targeting OX40 receptor is supposed to be differentiated from other approaches in the space.

Kyowa Kirin seems confident about this, which makes sense given they're calling it a key strategic priority now. Amgen's still manufacturing it, so that part stays the same. Curious to see how they push this forward solo, especially with the clinical data already in hand for atopic dermatitis. Not sure if this is them betting they can do better commercialization-wise, or if there were other strategic reasons.